Hunan Warrant Pharmaceutical (688799.SH): Loxoprofen Sodium Transdermal Patch Obtains Drug Registration Certificate
Warner Pharmaceuticals (688799.SH) announced that it has recently received the drug registration certificate for Loxoprofen Sodium Transdermal Patch issued by the National Medical Products Administration. The Loxoprofen Sodium Transdermal Patch is used for the treatment of inflammation and pain associated with the following diseases and symptoms: osteoarthritis, muscle pain, and swelling or pain due to trauma. The company's Loxoprofen Sodium Transdermal Patch obtained the drug registration certificate under the new classification as a Class 4 chemical drug, which is regarded as passing the consistency evaluation.
Hunan Warrant Pharmaceutical (688799.SH) announced that it has recently received the Drug Registration Certificate for Lornoxicam Sodium Transdermal Patch, approved and issued by the National Medical Products Administration. The Lornoxicam Sodium Transdermal Patch is used for the treatment of inflammation and pain associated with the following diseases and symptoms: osteoarthritis, muscle pain, and swelling or pain resulting from trauma. The company's Lornoxicam Sodium Transdermal Patch has obtained the drug registration certificate as a category 4 chemical drug under the new registration classification, which is considered to have passed the consistency evaluation.
Related Articles
GREEN INTL HLDG (02700) announced its interim results, with a shareholder loss of HKD 831,000, a year-on-year decrease of 76.43%.
Zhuhai Zhongfu Enterprise (000659.SZ) plans to transfer 100% equity of its subsidiary Hangzhou Zhongfu.
MELCO INT'L DEV (00200) announced its interim results, with a profit attributable to shareholders of HK$309 million, a year-on-year decrease of 11.79%.
GREEN INTL HLDG (02700) announced its interim results, with a shareholder loss of HKD 831,000, a year-on-year decrease of 76.43%.
Zhuhai Zhongfu Enterprise (000659.SZ) plans to transfer 100% equity of its subsidiary Hangzhou Zhongfu.
MELCO INT'L DEV (00200) announced its interim results, with a profit attributable to shareholders of HK$309 million, a year-on-year decrease of 11.79%.
RECOMMEND
